// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

Morphology classification of circulating tumor cells could be a predictor of recurrent disease in patients with non-small cell lung cancer after surgery.

Yun Wu - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).

Phillip Lee Palmbos - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Palbociclib

Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.

Shruti U. Gandhy - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CVac

A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.

Esther Pijnappel - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Irinotecan

The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement.

Veena M. Singh - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Detection and Quantification of Circulating Tumor Cells in PBMCs or Blood Using Flow Cytometry

Ming Lei - American Association of Immunologists (AAI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The significance of spontaneously immortalized B lymphocytes from patients with AIDS-related non-Hodgkin’s lymphoma and HIV-infected individuals

Ke Zhuang - American Association of Immunologists (AAI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

N/A

Non-therapeutic administration of antimicrobial growth promoters to interrogate suppression mechanisms of innate and adaptive immune responses using an ovine model of stress

Sandra T Clarke - American Association of Immunologists (AAI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

chlorotetracycline

Circulating tumor cell clusters exhibit enhanced immune evasion from natural killer cells (P1192)

Hin Ching Lo - American Association of Immunologists (AAI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

PROGRAMMED DEATH-LIGAND 1 POSITIVE AND NON-EPITHELIAL SUBTYPE IN CIRCULATING TUMOR CELLS PREDICT LOCALLY ADVANCED PROSTATE CANCER PROGRESSION AND GUIDE THE IMMUNOTHERAPY AFTER SURGERY

Ke Li - American Urological Association (AUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

hRPC

CIRCULATING TUMOR CELL SUBTYPES AND BASELINE T-CELL POPULATION AS PROGNOSTIC BIOMARKERS TO COMBINATION THERAPY WITH CABOZANTINIB, NIVOLUMAB, AND IPILIMUMAB IN METASTATIC GENITOURINARY CANCER PATIENTS

Heather Chalfin - American Urological Association (AUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cabozantinib

FEASIBILITY OF FINDING CIRCULATING TUMORS CELLS AND ASSIGNING PD-L1 RECEPTOR STATUS USING SINGLE-CELL TECHNOLOGY COMBINED WITH CELSEE GENESIS SYSTEM

Shaheen Alanee - American Urological Association (AUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PERIOPERATIVE DETECTION OF CIRCULATING TUMOR CELLS IN RADICAL OR PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA

Nobuhiro Haga - American Urological Association (AUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Mofezolac

DIGITAL PATHOLOGY OF CIRCULATING TUMOR CELLS WITH MORPHOLOGIC ANALYSIS IS FEASIBLE IN LOCALIZED BLADDER CANCER

Heather Chalfin - American Urological Association (AUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

CIRCULATING TUMOR CELLS MAY IMPROVE PSA ABILITY TO PREDICT POSITIVE PROSTATE BIOPSY IN PATIENTS WITH TOTAL SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4–10 NG/ML

Binshuai Wang - American Urological Association (AUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prospective study with circulating tumor cells as potential prognosis biomarker in metastatic colorectal cancer.

Virgilio Souza E Silva - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

N/A

Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.

Shubham Pant - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Microphthalmia, syndromic, 9

Adrucil injection

Clinical correlation of circulating tumor cell (CTC) PD-L1 and HLA I expression in metastatic renal cell carcinoma (mRCC) using exclusion-based sample preparation technology.

Hamid Emamekhoo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

N/A

Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer.

Heather Chalfin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Prevalence of ARV7 in Asian metastatic castrate-resistant prostate cancer (mCRPC) patients using multiple detection platforms.

Johan Chan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

N/A

Copyright © 2026. QuantiNova All rights reserved